Serology News and Research

RSS

Beckman Coulter introduces new SARS-CoV-2 IgM assay in countries accepting the CE Mark

Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M assay in countries accepting the CE Mark.

From Beckman Coulter Diagnostics 12 Nov 2020

Research shows a unique T cell receptor repertoire in MIS-C patients

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv in November 2020, as a response to superantigen activation.

11 Nov 2020

Mask wearing, social distancing considerably reduce incidence of many diseases

Measures to reduce the spread of COVID-19 through non-pharmaceutical interventions (NPIs) such as mask wearing and social distancing are a key tool in combatting the impact of the ongoing coronavirus pandemic.

10 Nov 2020

HSS presents research related to rheumatology and orthopedic surgery at 2020 ACR annual meeting

At this year's American College of Rheumatology virtual meeting, Hospital for Special Surgery (HSS) presented exciting research related to rheumatology and orthopedic surgery.

10 Nov 2020

How COVID death counts become the stuff of conspiracy theories

In the waning days of the campaign, President Donald Trump complained repeatedly about how the United States tracks the number of people who have died from COVID-19, claiming, "This country and its reporting systems are just not doing it right."

2 Nov 2020

Seroprevalence and immune response to SARS-CoV-2 in Paris

François Anna et al. published this study in a recent medRxiv* preprint paper, where they present the results of assessing the serological response in the selected population. They tested for specific IgG response against the SARS CoV-2 Nucleoprotein and Spike protein and performed a pseudo-neutralization assay in sera of urban dwellers in Paris.

30 Oct 2020

Study: 90% of patients have detectable antibodies up to 7 months post contracting COVID-19

A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) with an interdisciplinary team of clinicians and researchers from Faculdade de Medicina da Universidade de Lisboa (FMUL) and Centro Hospitalar Lisboa Norte (CHLN) and collaborators at Instituto Português do Sangue e Transplantação (IPST), shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19.

23 Oct 2020

University of Minnesota Medical School chosen as ‘Capacity Building Center’ for national network

The University of Minnesota Medical School's Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country.

9 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

Rapid, low-cost test for potential universal COVID-19 monitoring

An international team of researchers has presented a convenient, low-cost serology test to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could potentially be made available universally.

7 Oct 2020

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for assessing SARS-CoV-2 antibody assays and show robust performance metrics for the AbC-19 rapid test.

5 Oct 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Now, a recent study published on the preprint server medRxiv* in September 2020 shows the achievement of herd immunity for SARS-CoV-2 infection by at least some expatriate worker communities in Qatar.

29 Sep 2020

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

Tokyo citizens may have developed COVID-19 herd immunity, say researchers

Researchers in Japan and the United States have conducted a study showing that herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have developed among the citizens of Tokyo during the summer.

24 Sep 2020

FDA issues emergency use authorization for first serology point-of-care test for COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19.

24 Sep 2020

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

New research being presented at the ESCMID Conference on Coronavirus Disease (ECCVID, online 23-25 September) shows that, in a head-to-head comparison of five tests used to detect SARS-CoV-2 antibodies (known as 'immunoassays'), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results.

24 Sep 2020

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Researchers from the NHS Foundation Trust, University of Cambridge and Cambridge Clinical Laboratories have warned that until a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes available, antigen and antibody testing should be carried out among oncology nurses as part of routine patient care.

21 Sep 2020

Seropositive partners increase risk of COVID-19 but not obstetric complications in pregnant women

While earlier studies have shown the significance of serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant women, their partners have largely been excluded. Now, a new Danish study published on the preprint server medRxiv in September 2020 reports the impact of serologic testing in both pregnant women and their partners, as well as their newborns.

17 Sep 2020

Critical insights into COVID-19 exposure for healthcare workers

A recent Northwestern University Feinberg School of Medicine study published in the preprint server medRxiv in September 2020 shows that the use of standard guidelines of infection control, including personal protective equipment (PPE), helps to prevent the undue risk of infection among HCWs as well.

16 Sep 2020

Serology News and Research

Beckman Coulter introduces new SARS-CoV-2 IgM assay in countries accepting the CE Mark

Research shows a unique T cell receptor repertoire in MIS-C patients

Mask wearing, social distancing considerably reduce incidence of many diseases

HSS presents research related to rheumatology and orthopedic surgery at 2020 ACR annual meeting

How COVID death counts become the stuff of conspiracy theories

Seroprevalence and immune response to SARS-CoV-2 in Paris

Study: 90% of patients have detectable antibodies up to 7 months post contracting COVID-19

University of Minnesota Medical School chosen as ‘Capacity Building Center’ for national network

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Rapid, low-cost test for potential universal COVID-19 monitoring

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

Tokyo citizens may have developed COVID-19 herd immunity, say researchers

FDA issues emergency use authorization for first serology point-of-care test for COVID-19

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Seropositive partners increase risk of COVID-19 but not obstetric complications in pregnant women

Critical insights into COVID-19 exposure for healthcare workers

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News